Loading…
Septerna, Inc. is projected to rise to $43.04 by 2027, a +25% move from its current price of $34.45. SEPN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $33.41 | $34.46 | $35.54 | +0.03% |
| Aug 3 | $33.00 | $34.47 | $36.01 | +0.07% |
| Aug 4 | $32.69 | $34.48 | $36.38 | +0.10% |
| Aug 5 | $32.43 | $34.50 | $36.70 | +0.13% |
| Aug 6 | $32.20 | $34.51 | $36.98 | +0.17% |
| Aug 7 | $32.00 | $34.52 | $37.23 | +0.20% |
| Aug 8 | $31.82 | $34.53 | $37.47 | +0.24% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $31.82 | $34.53 | $37.47 | +0.24% |
| Week 2 | $30.83 | $34.61 | $38.86 | +0.47% |
| Week 3 | $30.11 | $34.69 | $39.97 | +0.71% |
| Week 4 | $29.53 | $34.78 | $40.96 | +0.95% |
| Week 5 | $29.03 | $34.86 | $41.85 | +1.18% |
| Week 6 | $28.60 | $34.94 | $42.69 | +1.42% |
| Week 7 | $28.21 | $35.02 | $43.48 | +1.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc.
and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Septerna, Inc. (SEPN) is a healthcare company with a current price of $34.20 and a market cap of $1.54B. It is ranked 2145. These figures place Septerna within the biomedical research and development space, operating under the Healthcare category.
The near-term price path is shown as neutral in 2026 with an average around $34.20 and a 2026 min of $23.09 and max of $43.57, suggesting a balanced but mid-single-digit upside potential. The longer horizon outlines a bullish trajectory, with the 2030 average at $69.00 and the 2050 average at $480.06, reflecting meaningful long-term upside when measured against today’s price. The forecast also highlights a progression of bullish sentiment from 2027 onward, underscoring the potential for sustained appreciation over multi-year horizons.
A major floor 33.0% below — a decisive break under it would weaken the trend.
The nearest floor, 8.4% below — buyers have tended to step in here.
The nearest ceiling, 9.8% above — a clean break opens room to run.
A major ceiling 18.7% above — clearing it would confirm fresh momentum.
Key SEPN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SEPN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $34.14 | Buy | $34.24 | Buy |
| MA 10 | $33.74 | Buy | $34.05 | Buy |
| MA 20 | $34.24 | Buy | $34.00 | Buy |
| MA 50 | $33.30 | Buy | $32.71 | Buy |
| MA 100 | $29.08 | Buy | $30.42 | Buy |
| MA 200 | $27.25 | Buy | $27.05 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.38 | Neutral |
| Stoch RSI (14) | 76.90 | Neutral |
| CCI (20) | 13.30 | Neutral |
| Williams %R (14) | -20.17 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 1.12 | Buy |
| Bollinger %B (20,2) | 0.54 | Neutral |
| Stochastic %K (14) | 79.83 | Neutral |
| TRIX (15) | 0.07 | Buy |
| Awesome (5,34) | -0.57 | Sell |
| Ultimate (7,14,28) | 51.56 | Neutral |
| Momentum (10) | 1.05 | Buy |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 34.60 | Sell |
| ADX (14) | 9.90 | Neutral |
| ATR (14) | 1.01 | Info |
The 30-day technical picture shows a bullish tilt. RSI(14) is 50, and the price is above the SMA50 of $32.18, with the SMA200 at $26.84. Key near-term support sits at $30.47 and resistance at $37.84. The thirty-day price range runs from a low of $27.04 to a high of $43.26, illustrating a wide trading band. Annualized volatility is 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $23.09 | $34.45 | $44.42 | 0% | Neutral | |
| $33.92 | $43.04 | $58.00 | +25% | Bullish | |
| $38.61 | $50.62 | $71.12 | +47% | Bullish | |
| $44.32 | $59.69 | $86.62 | +73% | Bullish | |
| $54.30 | $74.88 | $111.65 | +117% | Bullish | |
| $68.11 | $95.99 | $146.54 | +179% | Bullish | |
| $83.32 | $119.82 | $186.80 | +248% | Bullish | |
| $91.54 | $134.16 | $213.19 | +289% | Bullish | |
| $96.84 | $144.52 | $233.70 | +320% | Bullish | |
| $102.84 | $156.17 | $256.64 | +353% | Bullish | |
| $193.01 | $317.29 | $557.84 | +821% | Bullish | |
| $312.29 | $589.83 | $1,143.31 | +16.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $23.09 | $34.45 | $41.98 | +0.00% |
| September 2026 | $29.08 | $34.54 | $42.29 | +0.26% |
| October 2026 | $29.68 | $35.52 | $44.01 | +2.84% |
| November 2026 | $30.05 | $36.20 | $45.28 | +1.90% |
| December 2026 | $29.06 | $35.20 | $44.42 | -2.75% |
Click any year to see its month-by-month SEPN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, SEPN could reach as high as $44.42, with a base case around $34.45 and support toward $23.09 — roughly 0% from $34.45. A consolidation phase looks the most probable path here.
Expect SEPN to range from $33.92 to $58.00 through 2027. The $43.04 average target implies a +25% move from current prices. That is up +25% on the projected 2026 average. Momentum favours further upside here.
The SEPN price prediction for 2028 points to an average of $50.62 (low $38.61, high $71.12) — a potential gain of +47% on today's $34.45. Buyers look set to stay in control over this stretch.
In 2029, SEPN is projected to trade between $44.32 and $86.62, averaging $59.69 — a potential gain of +73% from today's $34.45. That is up +18% on the projected 2028 average. Momentum favours further upside here.
Septerna, Inc.'s 2030 outlook centres on $74.88, within a $54.30 to $111.65 range. That is up +25% on the projected 2029 average. That marks a +117% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, SEPN could reach as high as $146.54, with a base case around $95.99 and support toward $68.11 — roughly +179% from $34.45. Momentum favours further upside here.
Expect SEPN to range from $83.32 to $186.80 through 2032. The $119.82 average target implies a +248% move from current prices. That is up +25% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The SEPN price prediction for 2033 points to an average of $134.16 (low $91.54, high $213.19) — a potential gain of +289% on today's $34.45. Momentum favours further upside here.
In 2034, SEPN is projected to trade between $96.84 and $233.70, averaging $144.52 — a potential gain of +320% from today's $34.45. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Septerna, Inc.'s 2035 outlook centres on $156.17, within a $102.84 to $256.64 range. That is up +8% on the projected 2034 average. That marks a +353% change versus current levels. Momentum favours further upside here.
By 2040, SEPN could reach as high as $557.84, with a base case around $317.29 and support toward $193.01 — roughly +821% from $34.45. Buyers look set to stay in control over this stretch.
Expect SEPN to range from $312.29 to $1,143.31 through 2050. The $589.83 average target implies a +16.1x move from current prices. That is up +86% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SEPN today (≈ 29.027576 SEPN) could be worth
$17,121.25
+$16,121.25 (+1612%) by 2050 · US Dollar
Based on the average projected SEPN price of $589.83 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SEPNwould be worth at today's price.
$1,000 invested in SEPN on Jul 31, 2025 (≈ 80.580178 SEPN) would be worth
$2,775.99
+$1,775.99 (+177.6%) today · 2.78× · US Dollar
Based on a SEPN entry price of $12.41 vs. today's $34.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $33.1 | $1,040.79 | +4.1% |
| 1 month ago | $34.61 | $995.38 | -0.5% |
| 3 months ago | $23.61 | $1,459.13 | +45.9% |
| 6 months ago | $25.03 | $1,376.35 | +37.6% |
| 1 year ago | $12.41 | $2,775.99 | +177.6% |
| All time (1.8y) ago | $21.4 | $1,609.81 | +61.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SEPN forecast.
Our base-case forecast reaches $69.00 around 2030.
Implied market cap at $69.00: $3.11B
Looking farther out, the forecast paints a strong long-term upside. In 2026 the avg is $34.20 with a min of $23.09 and a max of $43.57, and ROI of 0 with a Neutral sentiment. The path then grows steadily into bullish territory, with 2027 avg $41.92 and 2028 avg $47.88, and 2029 avg $54.33—all with bullish sentiment and positive ROI figures (22.6, 40, and 58.9 respectively).
By 2030, the avg rises to $69.00 with a min of $48.47 and a max of $106.46 and ROI of 101.8, maintaining a bullish tone. The trajectory continues through 2031–2035 with higher averages and strong gains (e.g., 2031 avg $87.71, 2032 $109.65, 2033 $123.70, 2034 $128.21, 2035 $136.48). The long-term forecast reaches 2040 with an avg of $277.97 and ROI of 712.8, and 2050 with an avg of $480.06 and ROI of 1303.7, both labeled bullish.
These figures imply substantial upside potential over the next decades, tempered by the caveat that forecasts are estimates, not guarantees, and depend on market conditions and company developments.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $69.00, with a min of $48.47 and a max of $106.46, and an ROI of 101.8, with a bullish sentiment.
The long-term forecast portrays bullish sentiment from 2027 onward, with the average rising to $69.00 by 2030 and to $480.06 by 2050, and ROI reaching 101.8 by 2030 and 1303.7 by 2050.
Yes. The 2030 forecast lists a max of $106.46, indicating the possibility of exceeding $100 by 2030 according to the provided projections.
The current price is $34.20 and the market cap is $1.54B.
The 30-day picture shows a bullish sentiment with RSI(14) at 50, SMA50 of $32.18, SMA200 of $26.84, support at $30.47, resistance at $37.84, and a 30-day range of $27.04 to $43.26, with annualized volatility of 70%.
Septerna, Inc. Community Discussion
0Share your Septerna, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.